PVR and neoplasm: TIGIT can bind to CD155 of dendritic cells(DCs), triggering a cascade reaction indirectly hindering T cell function. It can also inhibit NK cell degranulation, produce cytokines, and mediate cytotoxicity against CD155+tumor cells.